Abstract
MicroRNAs (miRNAs) recently emerged with a key role in multiple myeloma (MM) pathophysiology and are considered important regulators of MM cell growth and survival. Since miRNAs can act either as oncogenes or tumour suppressors, the potential of targeting the miRNA network arises as a novel therapeutic approach for human cancer. Potential strategies based on miRNA therapeutics basically rely on miRNA inhibition or miRNA replacement approaches and take benefit respectively from the use of antagomirs or synthetic miRNAs as well as from lipid-based nanoparticles which allow an efficient miRNA-delivery. The availability of experimental in vivo platforms which recapitulate the growth of MM cells within the specific human bone marrow microenvironment in immunocompromised mice (SCID-hu and SCID-synth-hu) provides powerful systems for development of miRNA-based therapeutics in MM. Preliminary findings on the anti-MM activity of synthetic miRNAs in such experimental models offer a proof-of-principle that miRNA therapeutics is a promising opportunity for this still incurable disease representing the rationale for a new venue of investigation in this specific field.
Keywords: Experimental therapeutics, microRNA, miRNAs, multiple myeloma, nanotechnology, nucleic acid delivery, Argonaute protein, Glycine-tryptophan 182 kD proteins, Insulin-like growth factor-1, Molecular-targeted agents, Stable nucleic acid lipid particles, RNA-Induced Silencing Complex.
Current Cancer Drug Targets
Title:Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Volume: 12 Issue: 7
Author(s): P. Tagliaferri, M. Rossi, M. T. Di Martino, N. Amodio, E. Leone, A. Gulla, A. Neri and P. Tassone
Affiliation:
Keywords: Experimental therapeutics, microRNA, miRNAs, multiple myeloma, nanotechnology, nucleic acid delivery, Argonaute protein, Glycine-tryptophan 182 kD proteins, Insulin-like growth factor-1, Molecular-targeted agents, Stable nucleic acid lipid particles, RNA-Induced Silencing Complex.
Abstract: MicroRNAs (miRNAs) recently emerged with a key role in multiple myeloma (MM) pathophysiology and are considered important regulators of MM cell growth and survival. Since miRNAs can act either as oncogenes or tumour suppressors, the potential of targeting the miRNA network arises as a novel therapeutic approach for human cancer. Potential strategies based on miRNA therapeutics basically rely on miRNA inhibition or miRNA replacement approaches and take benefit respectively from the use of antagomirs or synthetic miRNAs as well as from lipid-based nanoparticles which allow an efficient miRNA-delivery. The availability of experimental in vivo platforms which recapitulate the growth of MM cells within the specific human bone marrow microenvironment in immunocompromised mice (SCID-hu and SCID-synth-hu) provides powerful systems for development of miRNA-based therapeutics in MM. Preliminary findings on the anti-MM activity of synthetic miRNAs in such experimental models offer a proof-of-principle that miRNA therapeutics is a promising opportunity for this still incurable disease representing the rationale for a new venue of investigation in this specific field.
Export Options
About this article
Cite this article as:
Tagliaferri P., Rossi M., T. Di Martino M., Amodio N., Leone E., Gulla A., Neri A. and Tassone P., Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429355
DOI https://dx.doi.org/10.2174/156800912802429355 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Immune Therapy in Pancreatic Cancer: Now and the Future?
Reviews on Recent Clinical Trials Novel Treatment of Acute Promyelocytic Leukemia: As<sub>2</sub>O<sub>3</sub>, Retinoic Acid and Retinoid Pharmacology
Current Pharmaceutical Biotechnology Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer
Current Cancer Drug Targets Equipping CAR-Modified T Cells with a Brake to Prevent Chronic Adverse Effects
Current Gene Therapy Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation
Current Medicinal Chemistry Anthracyclines Still Prove Effective in Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Hollow Inorganic Nanoparticles as Efficient Carriers for siRNA Delivery: A Comprehensive Review
Current Pharmaceutical Design Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Immune Deviation Strategies in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Toxin-Labeled Monoclonal Antibodies
Current Pharmaceutical Biotechnology Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations
Current Drug Metabolism The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry